Carlyle ups offer for UK's Vectura

6 August 2021

UK-based inhaled medicines developer Vectura (LSE: VEC), which jilted a first offer from the Carlyle Group in July in favor of a bid from tobacco company Philip Morris, today received and accepted a higher bid from the private equity firm.

Under the offer, accepting shareholders of the U.K. pharmaceuticals business will get 155 pence in cash for each share held, a 3.3% premium to Philip Morris' previously agreed takeover of 150 pence, valuing the bid at £958 million ($1.33 billion). Vectura’s shares were up 6.6% at 164.18 pence as trading was near to closing.

The acquisition will be effected through Murano Bidco, a newly-formed company indirectly controlled by funds managed by Carlyle Europe Partners.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK